» Articles » PMID: 2849604

In-vitro and In-vivo Antibacterial Activity of Fleroxacin, a New Fluorinated Quinolone

Overview
Date 1988 Oct 1
PMID 2849604
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

The in-vitro and in-vivo antibacterial activities of fleroxacin were compared with those of other new quinolones including NY-198. Fleroxacin showed potent activity against most members of the Enterobacteriaceae, Neisseria gonorrhoeae and Haemophilus influenzae, and good activity against Pseudomonas aeruginosa and staphylococci. Against these bacteria, the activity of fleroxacin was roughly comparable to that of norfloxacin, enoxacin, NY-198, and ofloxacin, but slightly less than that of ciprofloxacin. Fleroxacin strongly inhibited DNA supercoiling activity of DNA gyrase purified from Escherichia coli which may explain its high antibacterial activity. The protective effects of a single oral dose of fleroxacin in mice were greater than those of norfloxacin and comparable to or greater than that of ciprofloxacin, ofloxacin and NY-198 against systemic infections with Staphylococcus aureus, Esch. coli and Ps. aeruginosa, and Serratia marcescens.

Citing Articles

Attenuation of gentamicin-induced nephrotoxicity in rats by fleroxacin.

Beauchamp D, Laurent G, Grenier L, Gourde P, ZANEN J, Bergeron M Antimicrob Agents Chemother. 1997; 41(6):1237-45.

PMID: 9174177 PMC: 163893. DOI: 10.1128/AAC.41.6.1237.


Penetration of ciprofloxacin and fleroxacin into biliary tract.

Edmiston Jr C, Suarez E, Walker A, Demeure M, Frantzides C, SCHULTE W Antimicrob Agents Chemother. 1996; 40(3):787-91.

PMID: 8851613 PMC: 163200. DOI: 10.1128/AAC.40.3.787.


Pharmacokinetics of [18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography.

Fischman A, Livni E, Babich J, Alpert N, Bonab A, CHODOSH S Antimicrob Agents Chemother. 1996; 40(3):659-64.

PMID: 8851589 PMC: 163176. DOI: 10.1128/AAC.40.3.659.


Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography.

Fischman A, Livni E, Babich J, Alpert N, Liu Y, Thom E Antimicrob Agents Chemother. 1993; 37(10):2144-52.

PMID: 8257137 PMC: 192242. DOI: 10.1128/AAC.37.10.2144.


Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.

Balfour J, Todd P, Peters D Drugs. 1995; 49(5):794-850.

PMID: 7601015 DOI: 10.2165/00003495-199549050-00010.